Physician profile
Leo Labunsky
NPI 1306871330
$2,113.78
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $568 · 2021: $843 · 2022: $330 · 2023: $80.78 · 2024: $34.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $115.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $757.99 | 2021-2024 | |
| Amgen INC. | $326.80 | 2019-2023 | Repatha, Otezla |
| Allergan, INC. | $179.20 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $98.07 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $85.17 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $73.10 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.58 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $63.17 | 2020-2022 | |
| Pfizer INC. | $51.67 | 2019-2021 | |
| Viiv Healthcare Company | $41.03 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $40.09 | 2019 | |
| Bausch Health US, LLC | $39.28 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $38.32 | 2020 | |
| Paratek Pharmaceuticals, INC. | $34.64 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.09 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $32.53 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $31.37 | 2021 | |
| Philips North America LLC | $29.40 | 2019 | |
| Xeris Pharmaceuticals, INC. | $26.03 | 2021 | |
| Nabriva Therapeutics, Plc | $22.35 | 2020 | |
| Arbor Pharmaceuticals, INC. | $17.47 | 2021 | |
| Lilly USA, LLC | $14.25 | 2019 | |
| Strongbridge US INC. | $13.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Labunsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.